← Lakewood-Amedex Biotherapeutics (LABT)
Lakewood-Amedex Biotherapeutics SEC filings
Filter: All · 8-K · 10-Q · 10-K · Form 4
Delisting notice / failure to meet listing standard · Financial statements and exhibits
AI summary, unreviewedLakewood-Amedex Biotherapeutics receives Nasdaq delisting notice after bid price fell below $1.00 for 30 days and prior reverse split bars compliance period
Entry into a material definitive agreement · Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedLakewood-Amedex Biotherapeutics (LABT) redeems all 127,097 Series C preferred shares for $1.27 million in cash, eliminating conversion dilution
Submission of matters to a vote of security holders